circulating tumor DNA
Artemis DNA to Provide Datar Cancer Genetics Liquid Biopsy Tests in the US, Vietnam Under $250M Deal
Under the five-year exclusive agreement, Artemis DNA will offer Datar Cancer Genetics' Trucheck Pragma and Cancertrack tests in the US and Vietnam.
Having officially launched its Shield colorectal cancer screening assay as an LDT, Guardant stands to benefit from a head start in clinical establishment.
The firm shared performance study results at a recent meeting and said it has begun processing samples for its first major pharma customer.Â
At the AACR annual meeting, both companies shared new data on their technologies' performance in detecting early and late-stage cancers.
C2i Genomics Lays Groundwork for Global Launch of Whole-Genome Minimal Residual Disease Test
Premium
With EU lab partnerships and a newly announced CE mark, the company is poised for the first clinical implementations of its solid tumor residual disease test.
Feb 17, 2022
Dec 17, 2021
Nov 4, 2021
Guardant Health Q3 Revenues Up 27 Percent
Aug 5, 2021
Guardant Health Q2 Revenues Grow 39 Percent
May 19, 2021